Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined ~$6.35M in open-market shares over a 7-day window following the | Aug 14, 2026 |
| ANIP | CLUSTER | neutral | 3/10 | Two ANIP insiders sold a combined $281K in open-market sales over a 7-day window following a strong Q2 earnings beat. Th | Aug 14, 2026 |
| SNY | COURT-RULING | neutral | 2/10 | Sanofi lost a discovery dispute in a pending antitrust class action over alleged coordinated retraction of hospital disc | Aug 13, 2026 |
| ZNTL | PRESS-RELEASE | bearish | 6/10 | Zentalis Pharmaceuticals priced an underwritten public offering of 23 million shares at $3.50 per share, expecting ~$80. | Aug 13, 2026 |
| ATTO | INSIDER-BUY | bullish | 6/10 | Goldman Sachs Group Inc., a 10%+ owner of Attovia Therapeutics, purchased 85,000 shares for $1.78M on the open market at | Aug 13, 2026 |
| ATTO | CLUSTER | bullish | 8/10 | Five major 10% owners, including Sanofi, Redmile, venBio, Frazier Life Sciences, and Goldman Sachs, collectively purchas | Aug 13, 2026 |
| CUE | 144 | neutral | 2/10 | Sumita Ray, Corporate Secretary of Cue Biopharma, filed a Form 144 to sell 8,829 shares of common stock valued at approx | Aug 13, 2026 |
| ONC | CLUSTER | neutral | 4/10 | CEO John Oyler sold $46.3M of stock over two days (Aug 11-12) following a strong Q2 earnings beat that sent shares up ~1 | Aug 13, 2026 |
| WVE | CLUSTER | neutral | 3/10 | Three Wave Life Sciences directors sold a total of ~$132K in open-market shares over a one-week window, with the largest | Aug 13, 2026 |
| AMGN | CLUSTER | neutral | 2/10 | Three Amgen senior VPs (CCO, Business Development, Human Resources) sold a total of ~$2.45M in open-market shares over a | Aug 13, 2026 |
| XFOR | 144 | neutral | 2/10 | Chairman Adam Craig filed a Form 144 notice to sell 47,436 shares (~$0.22M) to cover tax withholding on vested RSUs, a m | Aug 13, 2026 |
| GOSS | 8-K | neutral | 5/10 | Gossamer Bio reported Q2 2026 GAAP net income of $16.9 million ($0.05 basic EPS) vs. a net loss of -$38.3 million (-$0.1 | Aug 13, 2026 |
| DARE | 8-K | mixed | 5/10 | Dare Bioscience reported Q2 2026 results with a net loss of -$0.20 per share, beating consensus estimates of -$0.33 by 3 | Aug 13, 2026 |
| SLXN | 8-K | bearish | 6/10 | Silexion Therapeutics Corp entered into a securities purchase agreement on August 11, 2026, to sell up to $2,500,005 of | Aug 13, 2026 |
| HURA | 8-K | neutral | 2/10 | TuHURA Biosciences drew an additional $650,000 under its existing $50M revolving credit facility with Parkview Holdings | Aug 13, 2026 |
| MSLE | 6-K | bullish | 6/10 | Satellos Bioscience reported Q2 2026 financial results, showing a net loss of $11.7M ($0.56/share) vs $5.6M ($0.39/share | Aug 13, 2026 |
| DYN | 144 | neutral | 2/10 | Director Douglas Kerr filed a Form 144 notice of intent to sell 2,443 shares of Dyne Therapeutics common stock, with an | Aug 13, 2026 |
| DYN | 144 | neutral | 2/10 | Erick Lucera, an officer of Dyne Therapeutics, filed a Form 144 on August 13, 2026, indicating intent to sell 1,797 shar | Aug 13, 2026 |
| BBIO | PRESS-RELEASE | bearish | 5/10 | BridgeBio announced a secondary offering of 5,000,000 shares by KKR Genetic Disorder L.P., with the company receiving no | Aug 13, 2026 |
| DYN | 144 | bearish | 6/10 | Atlas Venture Fund XI, L.P., a major venture capital insider, filed a Form 144 on August 13, 2026, indicating intent to | Aug 13, 2026 |
| NEU | 8-K | neutral | 2/10 | NewMarket Corp filed an 8-K announcing a quarterly dividend of $3.00 per share, payable October 1, 2026, to shareholders | Aug 13, 2026 |
| SLXN | 8-K | bearish | 7/10 | Silexion Therapeutics filed an 8-K to update its 2025 annual and Q1 2026 interim financial statements to reflect a 1-for | Aug 13, 2026 |
| MRK | CLUSTER | neutral | 2/10 | Two Merck EVPs sold a combined $2.81M in open-market stock over the past week, following the company's Q2 earnings beat | Aug 13, 2026 |
| GNLX | PRESS-RELEASE | neutral | 4/10 | Genelux reported Q2 2026 net loss of $0.21 per share, slightly below the $0.20 consensus estimate. The pre-revenue clini | Aug 13, 2026 |
| CLDI | PRESS-RELEASE | mixed | 5/10 | Calidi Biotherapeutics reported Q2 2026 results with a narrowed net loss of $4.2M ($2.94/share) vs $5.7M ($31.75/share) | Aug 13, 2026 |
| TIL | PRESS-RELEASE | neutral | 4/10 | Instil Bio reported Q2 2026 GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, driven by sharply | Aug 13, 2026 |
| TPST | PRESS-RELEASE | bearish | 7/10 | Tempest Therapeutics reported Q2 2026 net loss of $5.2M ($0.34/share), a narrower loss vs $7.9M ($2.07) a year ago, but | Aug 13, 2026 |
| INBX | PRESS-RELEASE | bearish | 6/10 | Inhibrx reported Q2 2026 EPS of -$2.34, a 26.5% miss vs the -$1.85 year-ago period, and zero revenue (vs $1.3M in Q2 202 | Aug 13, 2026 |
| TIL | 8-K | neutral | 4/10 | Instil Bio reported Q2 2026 results with a GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, dri | Aug 13, 2026 |
| NKTR | PRESS-RELEASE | bullish | 7/10 | Nektar Therapeutics reported Q2 2026 EPS of -$1.23, a 39.6% beat vs consensus of -$2.04, on revenue of $10.1M (slightly | Aug 13, 2026 |